ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective

M. L. Holt, A. James, K. Gutierrez, T. Sparkman, J. Banbury, D. Jones

University of Alabama at Birmingham Hospital, Birmingham, AL

Meeting: 2021 American Transplant Congress

Abstract number: 364

Keywords: Donors, marginal, Hepatitis C, Liver transplantation, Viral therapy

Topic: Clinical Science » Infectious Disease » Non-Organ Specific: Viral Hepatitis

Session Information

Session Name: Hepatitis C

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 8, 2021

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:30pm-6:35pm

Location: Virtual

*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution initiated a HCV donor positive/recipient negative (D+/R-) protocol that utilizes glecaprevir/pibrentasvir (G/P) in recipients of nucleic acid amplification testing (NAT) positive organs for 12 weeks beginning post-operative day three. Per protocol, NAT negative transplant recipients are initiated on treatment only after developing HCV viremia. Pharmacists play an integral role in G/P insurance approval and the medication acquisition process. The aim of this study is to assess antiviral efficacy and identify common barriers to G/P acquisition.

*Methods: The current study is a single-center, cohort analysis of recipients of a kidney or liver transplant from a HCV positive donor transplanted November 2019-June 2020. The primary objective is to determine rate of sustained virologic response (SVR12). Secondary objectives are to describe G/P cost and evaluate the prior authorization (PA) process.

*Results: Forty patients were included. Most patients were male (73%) African American (40%) renal transplant recipients (63%) who received anti-thymocyte globulin (58%). Thirty-one patients received NAT positive organs and were treated with G/P. The most common genotype was 1a (25%). All patients completed 12 weeks of therapy and achieved end of treatment response. No recipient of a NAT negative organ (n=9) developed viremia within the study period. All treated patients with a full data set available (87%) achieved SVR12. All G/P prescriptions required a PA with most (80%) requiring at least one appeal. The average time to PA approval was 3.35 days (range, 1-12). Pharmacy dispensing data was available for 27 patients indicating most patients required financial assistance (63%). Average copay, per fill, was less than $3.00 with average assistance equaling $1,265, $570 and $397 on each of three fills, respectively (range, $0-$3,892). Amounts rounded to nearest US dollar. Additional data collection is ongoing.

*Conclusions: Preliminary results suggest that the HCV donor positive/recipient negative protocol appears to be safe and effective in abdominal transplant recipients. Pharmacy involvement ensured patients were able to obtain DAA treatment to facilitate discharge.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Holt ML, James A, Gutierrez K, Sparkman T, Banbury J, Jones D. Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/transplanting-hepatitis-c-infected-organs-into-uninfected-recipients-a-pharmacy-perspective/. Accessed June 1, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences